TARS icon

Tarsus Pharmaceuticals

50.02 USD
-1.35
2.63%
Updated Apr 1, 3:10 PM EDT
1 day
-2.63%
5 days
-2.42%
1 month
17.09%
3 months
-9.30%
6 months
54.91%
Year to date
-9.30%
1 year
39.53%
5 years
143.05%
10 years
143.05%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

141% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 22

54% more capital invested

Capital invested by funds: $1.44B [Q3] → $2.22B (+$778M) [Q4]

18% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 55

17% more funds holding

Funds holding: 162 [Q3] → 190 (+28) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 8 (+0) [Q4]

10.42% less ownership

Funds ownership: 115.34% [Q3] → 104.93% (-10.42%) [Q4]

74% less call options, than puts

Call options by funds: $4.57M | Put options by funds: $17.5M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$58
16%
upside
Avg. target
$68
36%
upside
High target
$78
56%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Jefferies
Anthony Petrone
45% 1-year accuracy
10 / 22 met price target
16%upside
$58
Buy
Maintained
6 Mar 2025
Guggenheim
Eddie Hickman
44% 1-year accuracy
4 / 9 met price target
56%upside
$78
Buy
Maintained
26 Feb 2025
HC Wainwright & Co.
Oren Livnat
62% 1-year accuracy
31 / 50 met price target
46%upside
$73
Buy
Reiterated
26 Feb 2025
Barclays
Balaji Prasad
30% 1-year accuracy
13 / 44 met price target
20%upside
$60
Overweight
Maintained
26 Feb 2025
Oppenheimer
Francois Brisebois
29% 1-year accuracy
10 / 34 met price target
44%upside
$72
Outperform
Maintained
22 Jan 2025

Financial journalist opinion

Based on 4 articles about TARS published over the past 30 days

Neutral
GlobeNewsWire
2 weeks ago
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions.
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
Neutral
GlobeNewsWire
2 weeks ago
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Tarsus Announces Proposed $100.0 Million Public Offering
Positive
Seeking Alpha
3 weeks ago
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects.
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Neutral
GlobeNewsWire
3 weeks ago
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET.
Tarsus to Participate in Upcoming Investor Conference
Neutral
Seeking Alpha
1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
Neutral
GlobeNewsWire
2 months ago
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:
Tarsus to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
2 months ago
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
Neutral
GlobeNewsWire
2 months ago
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Charts implemented using Lightweight Charts™